Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.36 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23959861 | 0.87 | TMPRSS2 (0.47) | TMPRSS2PIK3CDACVRL1 | |
| SCHEMBL23959882 | 0.87 | TMPRSS2 (0.47) | TMPRSS2PIK3CDACVRL1CDK5CDK5R1 | |
| SCHEMBL25826835 | 0.87 | TMPRSS2 (0.47) | TMPRSS2PIK3CDACVRL1CDK5CDK5R1 | |
| SCHEMBL23959862 | 0.87 | TMPRSS2 (0.47) | TMPRSS2ACVRL1 | |
| SCHEMBL23960096 | 0.87 | TMPRSS2 (0.47) | TMPRSS2PIK3CDACVRL1CDK5CDK5R1 | |
| SCHEMBL23959859 | 0.87 | TMPRSS2 (0.47) | TMPRSS2PIK3CDACVRL1CDK5CDK5R1 | |
| SCHEMBL23959873 | 0.85 | TMPRSS2 (0.51) | TMPRSS2PIK3CDACVRL1CDK5CDK5R1 | |
| Gs-441524 SCHEMBL24667691 | 0.82 | TMPRSS2 (0.60) | TMPRSS2ACVRL1CDK5CDK5R1 | |
| Gs-441524 SCHEMBL24975226 | 0.82 | TMPRSS2 (0.60) | TMPRSS2ACVRL1CDK5CDK5R1 | |
| Gs-441524 SCHEMBL23870459 | 0.82 | TMPRSS2 (0.60) | TMPRSS2ACVRL1CDK5CDK5R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2021213288-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | 中国科学院上海药物研究所 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | TMPRSS2 145/4885PIK3CD 774/4885ACVRL1 712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.